Fed. Circ. Unsure If PTAB Has To Explain Axing Avastin Patent
The Federal Circuit appeared skeptical Thursday that drugmaker Genentech deserves a beefier explanation from the Patent Trial and Appeal Board about why it axed a patent covering the company's blockbuster cancer...To view the full article, register now.
Already a subscriber? Click here to view full article